Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Overexpression of BRD4 in Gastric Cancer and its Clinical Significance as a Novel Therapeutic Target

Author(s): Mengying Zhang, Hong Huang, Meijiao Wei, Mengjia Sun, Guojin Deng, Shuiqing Hu, Hongbo Wang* and Yanling Gong*

Volume 24, Issue 2, 2024

Published on: 12 July, 2023

Page: [167 - 177] Pages: 11

DOI: 10.2174/1568009623666230606164030

Price: $65

Abstract

Background: BRD4 is a member of the bromodomain and extra terminal domain (BET) family of proteins, containing two bromodomains and one extra terminal domain, and is overexpressed in several human malignancies. However, its expression in gastric cancer has not yet been well illustrated.

Objective: This study aimed to elucidate the overexpression of BRD4 in gastric cancer and its clinical significance as a novel therapeutic target.

Methods: Fresh gastric cancer tissues and paraffin-embedded specimens of gastric cancer patients were collected, and the BRD4 expression was examined by Western Blot Analysis (WB) and Immunohistochemistry Analysis (IHC), respectively. The possible relationship between BRD4 expression and the clinicopathological features as well as survival in gastric cancer patients was analyzed. The effect of BRD4 silencing on human gastric cancer cell lines was investigated by MTT assay, WB, wound healing assay, and Transwell invasion.

Results: The results showed that the expression level in tumor tissues and adjacent tissues was significantly higher than that in normal tissues, respectively (P < 0.01). BRD4 expression level in gastric cancer tissues was strongly correlated with the degree of tumor differentiated degree (P = 0.033), regional lymph nodes metastasis (P = 0.038), clinical staging (P = 0.002), and survival situation (P = 0.000), while the gender (P = 0.564), age (P = 0.926) and infiltrating depth (P = 0.619) of patients were not associated. Increased BRD4 expression resulted in poor overall survival (P = 0.003). In in vitro assays, BRD4 small interfering RNA resulted in significantly decreased BRD4 protein expression, therefore inhibiting proliferation, migration, and invasion of gastric cancer cells.

Conclusion: BRD4 might be a novel biomarker for the early diagnosis, prognosis, and therapeutic target in gastric cancer.

Keywords: Gastric cancer, BRD4, prognosis, siRNA, western blot, proliferation

« Previous Next »
Graphical Abstract

[1]
Recio-Boiles, A.; Babiker, H.M. Gastric Cancer; StatPearls: Treasure Island, FL, 2022.
[2]
Chen, Z.; Zhang, P.; Xi, H.; Wei, B.; Chen, L.; Tang, Y. Recent advances in the diagnosis, staging, treatment, and prognosis of advanced gastric cancer: A literature review. Front. Med., 2021, 8, 744839.
[http://dx.doi.org/10.3389/fmed.2021.744839] [PMID: 34765619]
[3]
Cotterman, R.; Jin, V.X.; Krig, S.R.; Lemen, J.M.; Wey, A.; Farnham, P.J.; Knoepfler, P.S. N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res., 2008, 68(23), 9654-9662.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-1961] [PMID: 19047142]
[4]
Taniguchi, Y.; Kurokawa, Y.; Takahashi, T.; Mikami, J.; Miyazaki, Y.; Tanaka, K.; Makino, T.; Yamasaki, M.; Nakajima, K.; Mori, M.; Doki, Y. Prognostic value of trefoil factor 3 expression in patients with gastric cancer. World J. Surg., 2018, 42(12), 3997-4004.
[http://dx.doi.org/10.1007/s00268-018-4737-0] [PMID: 30039286]
[5]
Zheng, Q.; Wu, F.; Dai, W.Y.; Zheng, D.C.; Zheng, C.; Ye, H.; Zhou, B.; Chen, J.J.; Chen, P. Aberrant expression of UCA1 in gastric cancer and its clinical significance. Clin. Transl. Oncol., 2015, 17(8), 640-646.
[http://dx.doi.org/10.1007/s12094-015-1290-2] [PMID: 25903045]
[6]
Zhang, C.; Yuan, W.; Wu, Y.; Wan, X.; Gong, Y. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells. Life Sci., 2021, 266, 118886.
[http://dx.doi.org/10.1016/j.lfs.2020.118886] [PMID: 33310044]
[7]
Wu, S.Y.; Lee, C.F.; Lai, H.T.; Yu, C.T.; Lee, J.E.; Zuo, H.; Tsai, S.Y.; Tsai, M.J.; Ge, K.; Wan, Y.; Chiang, C.M. Opposing functions of BRD4 isoforms in breast cancer. Mol. Cell, 2020, 78(6), 1114-1132.e10.
[http://dx.doi.org/10.1016/j.molcel.2020.04.034] [PMID: 32446320]
[8]
Fischer, D.; Bieber, T.; Li, Y.; Elsässer, H.P.; Kissel, T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: Effect of molecular weight on transfection efficiency and cytotoxicity. Pharm. Res., 1999, 16(8), 1273-1279.
[http://dx.doi.org/10.1023/A:1014861900478] [PMID: 10468031]
[9]
Ali, A.; Shafarin, J.; Unnikannan, H.; Al-Jabi, N.; Jabal, R.A.; Bajbouj, K.; Muhammad, J.S.; Hamad, M. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulation of HDAC1 in molecular subtypes of breast cancer. Int. J. Biol. Sci., 2021, 17(15), 4474-4492.
[http://dx.doi.org/10.7150/ijbs.62236] [PMID: 34803511]
[10]
Bauer, K.; Berghoff, A.S.; Preusser, M.; Heller, G.; Zielinski, C.C.; Valent, P.; Grunt, T.W. Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. Am. J. Cancer Res., 2021, 11(2), 530-545.
[PMID: 33575085]
[11]
Blee, A.M.; Liu, S.; Wang, L.; Huang, H. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. Oncotarget, 2016, 7(25), 38319-38332.
[http://dx.doi.org/10.18632/oncotarget.9513] [PMID: 27223260]
[12]
Fan, H.; Yuan, J.; Li, Y.; Jia, Y.; Li, J.; Wang, X.; Li, X. MKL1-induced lncRNA SNHG18 drives the growth and metastasis of non-small cell lung cancer via the miR-211-5p/BRD4 axis. Cell Death Dis., 2021, 12(1), 128.
[http://dx.doi.org/10.1038/s41419-021-03399-z] [PMID: 33500406]
[13]
Zhang, S.; Chen, Y.; Tian, C.; He, Y.; Tian, Z.; Wan, Y.; Liu, T. Dual-target inhibitors based on BRD4: Novel therapeutic approaches for cancer. Curr. Med. Chem., 2021, 28(9), 1775-1795.
[http://dx.doi.org/10.2174/0929867327666200610174453] [PMID: 32520674]
[14]
Shu, S.; Wu, H.J.; Ge, J.Y.; Zeid, R.; Harris, I.S.; Jovanović, B.; Murphy, K.; Wang, B.; Qiu, X.; Endress, J.E.; Reyes, J.; Lim, K.; Font-Tello, A.; Syamala, S.; Xiao, T.; Reddy, C.C.S.; Papachristou, E.K.; D’Santos, C.; Anand, J.; Hinohara, K.; Li, W.; McDonald, T.O.; Luoma, A.; Modiste, R.J.; Nguyen, Q.D.; Michel, B.; Cejas, P.; Kadoch, C.; Jaffe, J.D.; Wucherpfennig, K.W.; Qi, J.; Liu, X.S.; Long, H.; Brown, M.; Carroll, J.S.; Brugge, J.S.; Bradner, J.; Michor, F.; Polyak, K. Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer. Mol. Cell, 2020, 78(6), 1096-1113.e8.
[http://dx.doi.org/10.1016/j.molcel.2020.04.027] [PMID: 32416067]
[15]
Yin, M.; Guo, Y.; Hu, R.; Cai, W.L.; Li, Y.; Pei, S.; Sun, H.; Peng, C.; Li, J.; Ye, R.; Yang, Q.; Wang, N.; Tao, Y.; Chen, X.; Yan, Q. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nat. Commun., 2020, 11(1), 1833.
[http://dx.doi.org/10.1038/s41467-020-15290-0] [PMID: 32286255]
[16]
Ba, M.; Long, H.; Yan, Z.; Wang, S.; Wu, Y.; Tu, Y.; Gong, Y.; Cui, S. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c‐MYC. J. Cell. Biochem., 2018, 119(1), 973-982.
[http://dx.doi.org/10.1002/jcb.26264] [PMID: 28681984]
[17]
Qin, Z.; Wang, T.; Su, S.; Shen, L.; Zhu, G.; Liu, Q.; Zhang, L.; Liu, K.; Zhang, Y.; Zhou, Z.; Zhang, X.; Wen, L.; Yao, Y.; Sun, W.; Guo, Y.; Liu, K.; Liu, L.; Wang, X.; Wei, Y.; Wang, J.; Xiao, H.; Liu, P.; Bian, X.; Chen, D.; Wang, B. BRD4 promotes gastric cancer progression and metastasis through acetylation-dependent stabilization of snail. Cancer Res., 2019, 79(19), 4869-4881.
[http://dx.doi.org/10.1158/0008-5472.CAN-19-0442] [PMID: 31311807]
[18]
Song, H.; Shi, L.; Xu, Y.; Xu, T.; Fan, R.; Cao, M.; Xu, W.; Song, J. BRD4 promotes the stemness of gastric cancer cells via attenuating miR-216a-3p-mediated inhibition of Wnt/β-catenin signaling. Eur. J. Pharmacol., 2019, 852, 189-197.
[http://dx.doi.org/10.1016/j.ejphar.2019.03.018] [PMID: 30876979]
[19]
Zhang, M.; Qiu, B.; Sun, M.; Wang, Y.; Wei, M.; Gong, Y.; Yan, M. Preparation of Black pepper (Piper nigrum L.) essential oil nanoparticles and its antitumor activity on triple negative breast cancer in vitro. J. Food Biochem., 2022, 46(12), e14406.
[http://dx.doi.org/10.1111/jfbc.14406] [PMID: 36121189]
[20]
Walter, L.O.; Maioral, M.F.; Silva, L.O.; Speer, D.B.; Campbell, S.C.; Gallimore, W.; Falkenberg, M.B.; Santos-Silva, M.C. Involvement of the NF‐κB and PI3K/Akt/MTOR pathways in cell death triggered by stypoldione, an o‐quinone isolated from the brown algae Stypopodium zonale. Environ. Toxicol., 2022, 37(6), 1297-1309.
[http://dx.doi.org/10.1002/tox.23484] [PMID: 35128807]
[21]
Sekiguchi, M.; Oda, I.; Matsuda, T.; Saito, Y. Epidemiological trends and future perspectives of gastric cancer in eastern Asia. Digestion, 2022, 103(1), 22-28.
[http://dx.doi.org/10.1159/000518483] [PMID: 34515086]
[22]
Sexton, R.E.; Al Hallak, M.N.; Diab, M.; Azmi, A.S. Gastric cancer: A comprehensive review of current and future treatment strategies. Cancer Metastasis Rev., 2020, 39(4), 1179-1203.
[http://dx.doi.org/10.1007/s10555-020-09925-3] [PMID: 32894370]
[23]
Vogelaar, I.P.; van der Post, R.S.; Bisseling, T.M.; van Krieken, J.H.J.M.; Ligtenberg, M.J.L.; Hoogerbrugge, N. Familial gastric cancer: Detection of a hereditary cause helps to understand its etiology. Hered. Cancer Clin. Pract., 2012, 10(1), 18.
[http://dx.doi.org/10.1186/1897-4287-10-18] [PMID: 23231819]
[24]
Tan, P.; Yeoh, K.G. Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology, 2015, 149(5), 1153-1162.e3.
[http://dx.doi.org/10.1053/j.gastro.2015.05.059] [PMID: 26073375]
[25]
Bierne, H.; Hamon, M.; Cossart, P. Epigenetics and bacterial infections. Cold Spring Harb. Perspect. Med., 2012, 2(12), a010272.
[http://dx.doi.org/10.1101/cshperspect.a010272] [PMID: 23209181]
[26]
Feng, W.; Ding, Y.; Zong, W.; Ju, S. Non-coding RNAs in regulating gastric cancer metastasis. Clin. Chim. Acta, 2019, 496, 125-133.
[http://dx.doi.org/10.1016/j.cca.2019.07.003] [PMID: 31276633]
[27]
Grady, W.M.; Yu, M.; Markowitz, S.D. Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer. Gastroenterology, 2021, 160(3), 690-709.
[http://dx.doi.org/10.1053/j.gastro.2020.09.058] [PMID: 33279516]
[28]
Fujisawa, T.; Filippakopoulos, P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat. Rev. Mol. Cell Biol., 2017, 18(4), 246-262.
[http://dx.doi.org/10.1038/nrm.2016.143] [PMID: 28053347]
[29]
Filippakopoulos, P.; Knapp, S. Targeting bromodomains: Epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov., 2014, 13(5), 337-356.
[http://dx.doi.org/10.1038/nrd4286] [PMID: 24751816]
[30]
Wang, N; Wu, RL; Tang, DL; Kang, R The BET family in immunity and disease. Signal Transduct Tar., 2021, 6(1), 23.
[http://dx.doi.org/10.1038/s41392-020-00384-4]
[31]
Hu, Y.; Zhou, J.; Ye, F.; Xiong, H.; Peng, L.; Zheng, Z.; Xu, F.; Cui, M.; Wei, C.; Wang, X.; Wang, Z.; Zhu, H.; Lee, P.; Zhou, M.; Jiang, B.; Zhang, D. BRD4 inhibitor inhibits colorectal cancer growth and metastasis. Int. J. Mol. Sci., 2015, 16(1), 1928-1948.
[http://dx.doi.org/10.3390/ijms16011928] [PMID: 25603177]
[32]
Jiao, F.; Han, T.; Yuan, C.; Liang, Y.; Cui, J.; Zhuo, M.; Wang, L. Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer. Cancer Cell Int., 2020, 20(1), 55.
[http://dx.doi.org/10.1186/s12935-020-1135-0] [PMID: 32099528]
[33]
Tan, Y.F.; Wang, M.; Chen, Z.Y.; Wang, L.; Liu, X.H. Inhibition of BRD4 prevents proliferation and epithelial–mesenchymal transition in renal cell carcinoma via NLRP3 inflammasome-induced pyroptosis. Cell Death Dis., 2020, 11(4), 239.
[http://dx.doi.org/10.1038/s41419-020-2431-2] [PMID: 32303673]
[34]
Niu, X.; Wang, W.; Liang, T.; Li, S.; Yang, C.; Xu, X.; Li, L.; Liu, S. CPI‐203 improves the efficacy of anti‐PD‐1 therapy by inhibiting the induced PD‐L1 overexpression in liver cancer. Cancer Sci., 2022, 113(1), 28-40.
[http://dx.doi.org/10.1111/cas.15190] [PMID: 34727389]
[35]
Yigitliler, A.; Renner, J.; Simon, C.; Schneider, M.; Stubenrauch, F.; Iftner, T. BRD4S interacts with viral E2 protein to limit human papillomavirus late transcription. J. Virol., 2021, 95(11), e02032-20.
[http://dx.doi.org/10.1128/JVI.02032-20] [PMID: 33731454]
[36]
Wang, X.; Helfer, C.M.; Pancholi, N.; Bradner, J.E.; You, J. Recruitment of Brd4 to the human papillomavirus type 16 DNA replication complex is essential for replication of viral DNA. J. Virol., 2013, 87(7), 3871-3884.
[http://dx.doi.org/10.1128/JVI.03068-12] [PMID: 23365439]
[37]
Sun, H.Y.; Du, S.T.; Li, Y.Y.; Deng, G.T.; Zeng, F.R. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers. World J. Gastrointest. Oncol., 2022, 14(1), 75-89.
[http://dx.doi.org/10.4251/wjgo.v14.i1.75] [PMID: 35116104]
[38]
Saffar, H.; Okhovat, H.; Arbabsoleymani, S.; Tavangar, S.M.; Khoshnevisan, A.; Hajinasrollah, G.; Hamidi Afra, Z.; Saffar, H. The utility of phosphohistone H3 in inter-observer variability of mitotic count in meningioma, is there any benefit? Asian Pac. J. Cancer Prev., 2021, 22(7), 2049-2052.
[http://dx.doi.org/10.31557/APJCP.2021.22.7.2049] [PMID: 34319026]
[39]
Tu, Y.; Jiang, P.; Zhang, J.; Jiang, S.; Yi, Q.; Yuan, R. The positive threshold of the immunohistochemical parameter Ki67 for predicting the recurrence of cervical cancer. Int. J. Gynaecol. Obstet., 2022, 158(2), 330-337.
[http://dx.doi.org/10.1002/ijgo.14005] [PMID: 34735721]

Rights & Permissions Print Cite
Article Metrics
23
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy